Dengue 1,2,3,4 (attenuated) vaccine

ApprovedVaccine

Dengue 1,2,3,4 (attenuated) vaccine is one of 54 biologic programs targeting Rheumatic Disease. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Rheumatic DiseaseActive, not recruiting

DengueRecruiting

Rheumatic DiseaseApproved

Active, not recruiting

DenguePhase 3

Recruiting

Competition

Competitive Landscape

82 competitors in Rheumatic Disease

#DrugCompanyPhaseTrials

Anjeso

Boehringer Ingelheim

Approved

1 2

Oruvail

WWyeth-Lederle Vaccines

COVID-19 Vaccine

2 4

Jascayd

Cosentyx

1 6

Taltz

Eli Lilly

Phase 2

1 7

Bimzelx

UCB

Phase 2

1 8

Stelara

Johnson & Johnson

Phase 2

1 9

Tremfya

Johnson & Johnson

Phase 2

1 10

Skyrizi

AbbVie

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

Dengue

NCT06891950

Q4 2028

Post-ApprovalNot yet recruiting

Rheumatic Disease

NCT07087912

Clinical

Trials by Indication[1]

Efficacy and Safety1 trial

Phase III Trial to Evaluate Efficacy and Safety of a Tetravalent Dengue Vaccine

Unknown status·BButantan Institute·Phase 3·NCT02406729·16,935 enrolled

Rheumatic Disease1 trial

Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases

Not yet recruiting·UUniversity of Sao Paulo General Hospital·Phase 4·NCT07087912·477 enrolled

Immunogenicity1 trial

Phase II Trial to Evaluate Safety and Immunogenicity of a Dengue 1,2,3,4 (Attenuated) Vaccine

Unknown status·BButantan Institute·Phase 2·NCT01696422·300 enrolled

Dengue1 trial

Phase 3B, Double-blind, Randomized Study to Evaluate the Safety and Non-inferiority of the Humoral Immune Response of the Butantan Dengue Vaccine in Participants Aged 60 to 79 Years Compared to Participants Aged 40 to 59 Years

Recruiting·BButantan Institute·Phase 3·NCT06891950·997 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Dengue 1,2,3,4 (attenuated) vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dengue 1,2,3,4 (attenuated) vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dengue 1,2,3,4 (attenuated) vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Butantan Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Approved[1]
Company: BButantan Institute

Dengue 1,2,3,4 (attenuated) vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2028

Trials by Indication[1]

Efficacy and Safety1 trial

Rheumatic Disease1 trial

Immunogenicity1 trial

Dengue1 trial

References

Drug Info

Quick Facts

Related News